This Viewpoint uses FDA approval of tisagenlecleucel, the first chimeric antigen receptor T-cell (CAR-T) agent approved for human use, to discuss escalating drug prices for oncology therapies and the complex considerations of outcomes and value that should justify the pricing.
No takes yet. Share an insight, caveat, or question.
Bach et al. (2017) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: